Neurology

Horizon Discovery declines Abcam’s USD 367 million takeover bid Horizon Discovery has recently rejected a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing technique and has issued a strong rejection to the offer of Abcam. Horizon’s board believes that the bid undervalues the company due to which it has rejected the offer. Casma Therapeutics kick starts with USD 58.5 million for treatments targeting the cell's garbage disposal Casma Therapeutics is heading with a USD 58.5 million series a funding to aim at a range of conditions through a process called cell garbage disposal. Funding was backed by Third Rock,...